This inventor holds 2 USPTO granted patents and 2 published patent applications and 1 EPO patent. Top assignee: Synerkine Pharma B.v.. Active years: 2022-2025.
Company Filing History:
Years Active: 2022-2025
Title: Niels Eijkelkamp: Innovator in Fusion Protein Technology
Introduction
Niels Eijkelkamp is a prominent inventor based in Utrecht, Netherlands. He has made significant contributions to the field of biotechnology, particularly in the development of fusion proteins. With a total of 2 patents to his name, Eijkelkamp is recognized for his innovative approaches to addressing complex medical conditions.
Latest Patents
One of Eijkelkamp's latest patents involves a fusion protein comprising interleukin 13 and a regulatory cytokine. This invention includes a nucleic acid molecule encoding the fusion protein, a vector containing this nucleic acid, and a host cell that incorporates the nucleic acid or vector. The fusion protein is designed for use in the prevention or treatment of conditions characterized by pathological pain, chronic pain, neuro-inflammation, and neurodegeneration. This groundbreaking work highlights the potential of gene therapy vectors in modern medicine.
Career Highlights
Eijkelkamp is currently associated with Synerkine Pharma B.V., where he continues to advance his research and development efforts. His work is pivotal in the exploration of therapeutic solutions that leverage the power of fusion proteins.
Collaborations
Eijkelkamp collaborates with notable colleagues, including Cornelis Erik Hack and Judith Prado Sanchez. These partnerships enhance the innovative capacity of his projects and contribute to the advancement of their shared goals in biotechnology.
Conclusion
Niels Eijkelkamp stands out as a key figure in the field of fusion protein technology. His inventions and collaborations are paving the way for new therapeutic strategies that could significantly impact the treatment of various medical conditions.